

Acknowledgement

This study was supported by a National Cancer Center Research and Development Grant (Grant Number 28-A-21).

References

1. Mariano C, Ionescu DN, Cheung WY, et al. Thymoma: A population-based study of the management and outcomes for the province of British Columbia. *J Thorac Oncol.* 2013;8:109-117. doi: 10.1097/JTO.0b013e318276241c
2. Bretti S, Berruti A, Loddo C, et al. Multimodal management of stages III — IVa malignant thymoma. *Lung Cancer.* 2004;44:69-77. doi: 10.1016/j.lungcan.2003.09.022
3. Kondo K, Monden Y. Therapy for thymic epithelial tumors: A clinical study of 1,320 patients from Japan. *Ann Thorac Surg.* 2003;76:878-884.
4. Leuzzi G, Rocco G, Ruffini E, et al. Multimodality therapy for locally advanced thymomas: A propensity score-matched cohort study from the European Society of Thoracic Surgeons Database. *J Thorac Cardiovasc Surg.* 2016;151:47-57. doi:

10.1016/j.jtcvs.2015.08.034

5. Schmitt J, Loehrer PJ. The role of chemotherapy in advanced thymoma. *J Thorac Oncol.* 2010;5:S357-S360. doi: 10.1097/JTO.0b013e3181f21129
6. Ruffini E, Van Raemdonck D, Detterbeck F, et al. Management of thymic tumors: A survey of current practice among members of the european society of thoracic surgeons. *J Thorac Oncol.* 2011;6:614-623. doi: 10.1097/JTO.0b013e318207cd74
7. Shepherd A, Riely G, Detterbeck F, et al. Thymic carcinoma management patterns among International Thymic Malignancy Interest Group (ITMIG) physicians with consensus from the Thymic Carcinoma Working Group. *J Thorac Oncol.* 2017;12:745-751. doi: 10.1016/j.jtho.2016.11.2219
8. Riely GJ, Huang J. Induction therapy for locally advanced thymoma. *J Thorac Oncol.* 2010;5:S323-S326. doi: 10.1097/JTO.0b013e3181f20e90
9. Girard N, Mornex F, Van Houtte P, Cordier JF, Van Schil P. Thymoma: A focus on current therapeutic management. *J Thorac Oncol.* 2009;4:119-126. doi: 10.1097/JTO.0b013e31818e105c.

10. Koppitz H, Rockstroh JK, Schüller H, et al. State-of-the-art classification and multimodality treatment of malignant thymoma. *Cancer Treat Rev.* 2012;38:540-548. doi: 10.1016/j.ctrv.2011.11.010
11. Lucchi M, Ambroggi MC, Duranti L, et al. Advanced stage thymomas and thymic carcinomas: Results of multimodality treatments. *Ann Thorac Surg.* 2005;79:1840-1844. doi: 10.1016/j.athoracsur.2004.12.047
12. Rena O, Mineo TC, Casadio C. Multimodal treatment for stage IVA thymoma: A proposable strategy. *Lung Cancer.* 2012;76:89-92. doi: 10.1016/j.lungcan.2011.10.004
13. Evans TL, Lynch TJ. Role of chemotherapy in the management of advanced thymic tumors. *Semin Thorac Cardiovasc Surg.* 2005;17:41-50.
14. Falkson CB, Bezjak A, Darling G, et al. The management of thymoma: A systematic review and practice guideline. *J Thorac Oncol.* 2009;4:911-919.
15. Yamada Y, Yoshino I, Nakajima J, et al. Surgical outcomes of patients with stage III thymoma in the Japanese nationwide database. *Ann Thorac Surg.* 2015;100:961-967. doi: 10.1016/j.athoracsur.2015.04.059

16. Detterbeck FC, Stratton K, Asanuma H, et al. The IASLC / ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM Classification of Malignant Tumors. *J Thorac Oncol*. 2014;9:S65-S72. doi: 10.1097/JTO.0000000000000290
17. Ahmad U, Yao X, Detterbeck F, et al. Thymic carcinoma outcomes and prognosis: Results of an international analysis. *J Thorac Cardiovasc Surg*. 2015;149:95-100. doi: 10.1016/j.jtcvs.2014.09.124
18. Girard N, Marx A, Peters S; ESMO Guidelines Committee. Thymic epithelial tumours : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015;26:v40-v55. doi: 10.1093/annonc/mdv277
19. Thymomas and Thymic Carcinomas. In: NCCN Clinical Practice Guidelines in Oncology. 2018. https://www.nccn.org/professionals/physician_gls/default.aspx (19 January 2019, date last accessed)
20. Iwamoto M, Nakamura F, Higashi T. Monitoring and evaluating the quality of cancer care in Japan using administrative claims data. *Cancer Sci*. 2016;107:68-

75. doi: 10.1111/cas.12837
21. Higashi T, Nakamura F, Shibata A, Emori Y, Nishimoto H. The national database of hospital-based cancer registries : a nationwide infrastructure to support evidence-based cancer care and cancer control policy in Japan. *Jpn J Clin Oncol*. 2014;44:2-8. doi: 10.1093/jjco/hyt013
22. World Health Organization. International Classification of Diseases for Oncology (ICD-O-3).
3rd edn. <https://www.who.int/classifications/icd/adaptations/oncology/en/> (19 January 2019,
date last accessed)
23. Sobin L, Wittekind C. TNM Classification of Malignant Tumours (UICC). 7th edn. New York: Wiley-Liss 2009.
24. Tsukada Y, Higashi T, Shimada H, Kikuchi Y, Terahara A. The use of neoadjuvant therapy for resectable locally advanced thoracic esophageal squamous cell carcinoma in an analysis of 5016 patients from 305 designated

- cancer care hospitals in Japan. *Int J Clin Oncol*. 2018;23:81-91. doi: 10.1007/s10147-017-1178-y
25. Marx A, Chan JKC, Coindre J-M, et al. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. *J Thorac Oncol*. 2015;10:1383-1395. doi: [10.1097/JTO.0000000000000654](https://doi.org/10.1097/JTO.0000000000000654)
26. SEER Summary Staging Manual. <http://seer.cancer.gov/tools/ssm/>; (19 January 2019, date last accessed)
27. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. *Cancer*. 1990;68:30-33.
28. Lemma GL, Lee J, Aisner SC, Langer CJ, Tester WJ, Johnson DH. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. *J Clin Oncol*. 2011;29:2060-2065. doi: 10.1200/JCO.2010.32.9607
29. Hirai F, Yamanaka T, Taguchi K, et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. *Ann Oncol*. 2015;26:363-368. doi: 10.1093/annonc/mdu541

30. Agatsuma T, Koizumi T, Kanda S, et al. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. *J Thorac Oncol*. 2011;6:2130-2134. doi: 10.1097/JTO.0b013e31822e71c0
31. Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2015;16:1630-1638. doi: 10.1016/S1470-2045(15)00305-8
32. Hirai F, Seto T, Yamanaka T, et al. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma. *Jpn J Clin Oncol*. 2013;43:1018-1022. doi:10.1093/jjco/hyt106
33. Furukawa I, Narukawa M. Analysis of the situation of new indication approvals based on “Kouchi-shinsei” and consideration of measures for its effective utilization. *Jpn J Clin Pharmacol Ther*. 2014;45:59-62.
34. Cho J, Kim HS, Ku BM, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. *J Clin Oncol*.

2018;in press. doi: 10.1200/JCO.2017.77.3184

35. Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm , single-centre , phase 2 study. *Lancet Oncol.* 2018;19:347-355. doi: 10.1016/S1470-2045(18)30062-7
36. Thomas A, Rajan A, Berman A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. *Lancet Oncol.* 2016;16:177-186. doi: 10.1016/S1470-2045(14)71181-7
37. Zucali PA, De Pas T, Palmieri G, et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. *J Clin Oncol.* 2018;36:342-349. doi: 10.1200/JCO.2017.74.4078

Table 1. Patient characteristics

All Patients (N = 1360)	Thymoma (N = 813)	Thymic carcinoma (N = 547)	<i>p</i> value
	N (%) or N		